首页 | 本学科首页   官方微博 | 高级检索  
检索        


Inverse relationship between patient peripheral blood CD34+ cell counts and collection efficiency for CD34+ cells in two automated leukapheresis systems
Authors:Heuft H G  Dubiel M  Rick O  Kingreen D  Serke S  Schwella N
Institution:Blood Bank and Division of Hematology/Oncology, Department of Internal Medicine, Charité University Hospital/Virchow Clinic, Humboldt University, Berlin, Germany. heuft.hans-gert@mh-hannover.de
Abstract:BACKGROUND: The purpose of this study was to analyze the CD34 cell collection efficiency (CE) of automated leukapheresis protocols of two blood cell separators (Spectra, COBE AutoPBSC protocol] and AS104, Fresenius PBSC-Lym, protocol]) for peripheral blood progenitor cell (PBPC) harvest in patients with malignant diseases. STUDY DESIGN AND METHODS: PBPCs were collected by the Spectra AutoPBSC protocol in 95 patients (123 collections) and the AS104 PBSC-Lym protocol in 87 patients (115 harvests). Patients underwent a median of one (range, 1-4) conventional-volume apheresis procedure of 10.8 L (9.0-13.9) to obtain a target cell dose of > or =2.5 x 10(6) CD34+ cells per kg. RESULTS: The median overall CD34 CE was significantly better on the AS104 than on the Spectra: 55.8 percent versus 42.4 percent (p = 0.000). This was also true below (59.2% vs. 50.1%; p = 0.022) and above (51.2% vs. 41.3%; p = 0.001) the preleukapheresis threshold of 40 CD34+ cells per microL needed to collect a single-apheresis autograft. However, at > or =40 circulating CD34+ cells per microL, both cell separators achieved the target of > or =2.5 x 10(6) CD34+ cells per kg. The CD34 CE dropped significantly, from 59.2 percent at <40 cells per microL to 51.2 percent at > or =40 cells per microL on the AS104 (p = 0.017) and from 50.1 percent to 41.3 percent on the Spectra (p = 0.033). CONCLUSION: Whereas the CD34 CE was significantly different with the AS104 and the Spectra, the CD34 CE of both machines correlated inversely with peripheral blood CD34+ cell counts, showing a significant decline with increasing numbers of circulating CD34+ cells. Nevertheless, at > or 40 preapheresis CD34+ cells per microL, sufficient hematopoietic autografts of > or =2.5 x 10(6) CD34+ cells per kg were harvested by a single conventional-volume (11 L) leukapheresis on both cell separators.
Keywords:AML = acute myelocytic leukemia  BC = breast cancer  CD34 CE = the CE of CD34+ cells  CE = collection efficiency  CPM = cyclophosphamide 2‐4 g/m2  DexaBEAM = dexamethasone 120 mg  carmustine 60 mg/m2  etoposide 300 mg/m2  cytarabine 800 mg/m2  melphalan 30 mg/m2  GCC = germ cell cancer  HD = Hodgkin's disease  MM = multiple myeloma  NHL = non‐Hodgkin's lymphoma  PB = peripheral blood  PBPC(s) = peripheral blood progenitor cell(s)  TI = paclitaxel 175 mg/m2  ifosfamide 5 g/m2  VIP‐E = etoposide 500 mg/m2  ifosfamide 4 g/m2  cisplatinum 50 mg/m2  epidoxorubicin 50 mg/m2
本文献已被 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号